Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 11/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12354037 | 0.93 | CYP1A1 (0.65) | CYP1A1GRIN1GRIN2BDRD2DRD3 | |
| SCHEMBL14217366 | 0.86 | CYP1A1 (0.46) | CYP1A1 | |
| SCHEMBL14119563 | 0.83 | CYP1A1 (0.64) | CYP1A1DRD2DRD3KCNH2S1PR1 | |
| SCHEMBL14217376 | 0.83 | CYP1A1 (0.64) | CYP1A1GRIN1GRIN2BDRD2DRD3 | |
| SCHEMBL12353816 | 0.83 | CYP1A1 (0.63) | CYP1A1DRD2DRD3KCNH2S1PR1 | |
| SCHEMBL12353769 | 0.82 | CYP1A1 (0.68) | CYP1A1GRIN1GRIN2BDRD2DRD3 | |
| SCHEMBL12353766 | 0.80 | CYP1A1 (0.70) | CYP1A1GRIN1GRIN2BDRD2DRD3 | |
| SCHEMBL14119561 | 0.79 | CYP1A1 (0.72) | CYP1A1DRD2DRD3KCNH2 | |
| SCHEMBL14119647 | 0.79 | CYP1A1 (0.63) | CYP1A1DRD2DRD3KCNH2S1PR1 | |
| SCHEMBL14217351 | 0.78 | CYP1A1 (0.39) | CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | CYP1A1 1777/4885GRIN1 3676/4885GRIN2B 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.